bexarotene has been researched along with paclitaxel in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (64.29) | 29.6817 |
| 2010's | 5 (35.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Talele, TT | 1 |
| Cohen, MH; Flamm Honig, S; Hirschfeld, S; Ibrahim, A; Johnson, JR; O'Leary, JJ; Pazdur, R; White, RM; Williams, GA | 1 |
| Lamph, WW; Prudente, RY; Yen, WC | 1 |
| Bissonnette, RP; Cooke, TA; Corpuz, MR; Lamph, WW; Negro-Vilar, A; Prudente, RY; Yen, WC | 1 |
| Lamph, WW; Yen, WC | 2 |
| Bissonnette, RP; Fan, B; Hermann, TW; Lamph, WW; Negro-Vilar, A; Roegner, K; Tooker, P; Yen, WC | 1 |
| Tyagi, P | 1 |
| Blumenschein, GR; Dziewanowska, ZE; Gatzemeier, U; Jotte, RM; Khuri, FR; Le Treut, J; Miller, WH; Negro-Vilar, A; Sun, SL; von Pawel, J; Zhang, JK | 1 |
| Bair, SM; Cherpelis, BS; Fenske, NA; Glass, LF; Marquez, CB; Smithberger, EE; Wenham, RM | 1 |
| Chu, Q; Jacobs, CD; Lopez-Anaya, A; Rodon, J; Rowinsky, EK; Takimoto, CH; Wakelee, HA | 1 |
2 review(s) available for bexarotene and paclitaxel
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Natural-Products-Inspired Use of the gem-Dimethyl Group in Medicinal Chemistry.
Topics: Animals; Biological Products; Chemistry, Pharmaceutical; Humans | 2018 |
3 trial(s) available for bexarotene and paclitaxel
| Article | Year |
|---|---|
Bexarotene in combination with chemotherapy fails to prolong survival in patients with advanced non-small-cell lung cancer: results from the SPIRIT I and II trials.
Topics: Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Tetrahydronaphthalenes; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Humans; Hypertriglyceridemia; Lung Neoplasms; Male; Middle Aged; Neoplasm Transplantation; Paclitaxel; Survival Analysis; Tetrahydronaphthalenes | 2008 |
A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC).
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Humans; Hypolipidemic Agents; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Retinoid X Receptors; Tetrahydronaphthalenes | 2012 |
9 other study(ies) available for bexarotene and paclitaxel
| Article | Year |
|---|---|
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene.
Topics: Anastrozole; Anticarcinogenic Agents; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Arsenic Trioxide; Arsenicals; Bexarotene; Breast Neoplasms; Drug Approval; Female; Humans; Leukemia, Promyelocytic, Acute; Lymphoma, T-Cell, Cutaneous; Nitriles; Oxides; Paclitaxel; Tamoxifen; Tetrahydronaphthalenes; Triazoles; United States; United States Food and Drug Administration | 2001 |
Synergistic effect of a retinoid X receptor-selective ligand bexarotene (LGD1069, Targretin) and paclitaxel (Taxol) in mammary carcinoma.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Cell Death; Female; Mammary Neoplasms, Experimental; Paclitaxel; Rats; Tetrahydronaphthalenes; Tumor Cells, Cultured | 2004 |
A selective retinoid X receptor agonist bexarotene (Targretin) prevents and overcomes acquired paclitaxel (Taxol) resistance in human non-small cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bexarotene; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Mutation; Paclitaxel; Retinoid X Receptors; Survival Rate; Tetrahydronaphthalenes; Transplantation, Heterologous; Tumor Cells, Cultured | 2004 |
The selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bexarotene; Breast Neoplasms; Cisplatin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Endothelial Cells; Female; Humans; Mice; Mice, Nude; Neoplasm Invasiveness; Neovascularization, Pathologic; Paclitaxel; Retinoid X Receptors; Survival Rate; Tetrahydronaphthalenes; Umbilical Veins | 2005 |
The retinoid X receptor agonist bexarotene (Targretin) synergistically enhances the growth inhibitory activity of cytotoxic drugs in non-small cell lung cancer cells.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Phytogenic; Bexarotene; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Interactions; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Paclitaxel; Tetrahydronaphthalenes; Transplantation, Heterologous; Vinblastine; Vinorelbine | 2005 |
A selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bexarotene; Cell Line, Tumor; Cell Proliferation; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Male; Mice; Mice, Nude; Paclitaxel; Prostatic Neoplasms; Retinoid X Receptors; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Tetrahydronaphthalenes | 2006 |
Multiple keratoacanthomas arising in the setting of sorafenib therapy: novel chemoprophylaxis with bexarotene.
Topics: Adenocarcinoma, Papillary; Anticarcinogenic Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bexarotene; Carboplatin; Clinical Trials as Topic; Cystadenocarcinoma, Serous; Dose-Response Relationship, Drug; Female; Humans; Hypertriglyceridemia; Hypothyroidism; Keratoacanthoma; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Ovarian Neoplasms; Paclitaxel; Phenylurea Compounds; Pyridines; Skin Diseases; Sorafenib; Tetrahydronaphthalenes | 2009 |